Director/PDMR Shareholding

RNS Number : 6290S

Dechra Pharmaceuticals PLC

18 March 2016

 

18 March 2016

Dechra^® Pharmaceuticals PLC

(Dechra or the Company)

Director shareholding 

Exercise of LTIP options:

Dechra Pharmaceuticals PLC announces that on 17 March 2016, the following Directors exercised nil cost options over ordinary shares of 1p each in the Company. The options were granted to them on 5 March 2013 pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP).

Ian Page sold sufficient shares (acquired pursuant to the LTIP exercise) in order to fund the resulting tax liability.  

Name	Capacity	Options Exercised	Shares Sold	Sale Price per share	Total beneficial shareholding following this announcement	Percentage of issued share capital
Ian Page	Director	87,905	41,440	£12.100186	752,166	0.812%
Tony Griffin	Director	32,027	Nil	N/A	52,104	0.056%

The exercise of the options was subject to the achievement of performance conditions which vested at 93.1% of the total award.

For further information, please contact:

Suzana Cross, General Counsel and Company Secretary                

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

RDSAKFDDPBKDNND